Gentium Submits New Drug Application to FDA

Symbols: GENT
Posted in: News, FDA
Share

Gentium S.p.A. (NASDAQ: GENT) today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for Defibrotide for the treatment of hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem-cell transplantation.


 
 
< Previous
Focus Media Announces Repurchase of 1.96M Shares From Fosun International at $30.67 per ADS
Next >
Compuware Acquires dynaTrace software for $256M
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust